3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
250
Lymphoma
137
Leukemia
124
Burkitt Lymphoma
90
Leukemia, Myeloid, Acute
69
Lymphoma, Non-Hodgkin
65
Lymphoma, Large B-Cell, Diffuse
59
Myelodysplastic Syndromes
54
Leukemia, Lymphocytic, Chronic, B-Cell
49
Lymphoma, Mantle-Cell
47
Hodgkin Disease
47
Lymphoma, Follicular
45
Leukemia, Myeloid, Accelerated Phase
39
Multiple Myeloma
34
Lymphoma, Large-Cell, Immunoblastic
33
Leukemia, Myeloid, Chronic-Phase
33
Recurrence
32
Blast Crisis
32
Lymphoma, B-Cell, Marginal Zone
31
Congenital Abnormalities
31
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
30
Myeloproliferative Disorders
30
Leukemia, Biphenotypic, Acute
30
Graft vs Host Disease
30
Leukemia, Myelomonocytic, Chronic
28
Dendritic Cell Sarcoma, Interdigitating
25
Neoplasms, Plasma Cell
22
Primary Myelofibrosis
21
Lymphoma, T-Cell, Cutaneous
20
Lymphoma, Large-Cell, Anaplastic
20
Interventions
glucarpidase
2
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
ripretinib
1
mirabegron
1
gamma-Glutamyl Hydrolase
1
Sitagliptin Phosphate
1
Rituximab
1
Methotrexate
1
Leucovorin
1
Lenalidomide
1
Eplerenone
1
Duration of Therapy
1
Cyclophosphamide
1
Cilengitide
1
Carboxypeptidases
1
Bendamustine Hydrochloride
1
Azacitidine
1
3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Renal Insufficiency
×
Methotrexate
×
Lymphoid
×
Clear all
NCT00634504
2022-06-06
LVPK
BTG International Inc.
Phase 1
Completed
20 enrolled
9 charts